MURA / Mural Oncology plc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mural Oncology plc

EX-99.2 Exhibit 99.2 Mural Oncology plc Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland www.muraloncology.com If you have sold or otherwise transferred all of your shares in Mural Oncology plc please send this letter as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or tr

DIRECTOR’S IRREVOCABLE UNDERTAKING

EX-2.3 Exhibit 2.3 DIRECTOR’S IRREVOCABLE UNDERTAKING PRIVATE AND CONFIDENTIAL To XOMA Royalty Corporation, a Nevada corporation (“Bidder”) XRA 5 Corp. (“Bidco”) From The director whose name and address are set out in Schedule 1 August 2025 Dear Sirs, I refer to the proposed acquisition of Mural Oncology plc (the “Target”) by Bidco, a wholly owned direct subsidiary of Bidder. Under the proposed tr

Mural Oncology plc

EX-99.3 Exhibit 99.3 Mural Oncology plc Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland www.muraloncology.com NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION DATE: 20 August 2025 TO: Employees/employee representatives of Mural Oncology plc (the

CONDITIONS OF THE ACQUISITION AND THE SCHEME

EX-2.2 Exhibit 2.2 CONDITIONS OF THE ACQUISITION AND THE SCHEME The Acquisition and the Scheme will comply with the Irish Takeover Rules, the Irish Companies Act and, where relevant, any applicable requirements of the Exchange Act and the Nasdaq, and will be subject to the terms and conditions set out in this Announcement and to be set out in the Scheme Document. The Acquisition and the Scheme are

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

EX-99.1 Exhibit 99.1 Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., August 20, 2025, (GLOBE NEWSWIRE) – Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2025 Mural Oncology pl

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commissi

DATED AUGUST 20, 2025 XOMA ROYALTY CORPORATION XRA 5 CORP. MURAL ONCOLOGY PLC TRANSACTION AGREEMENT

EX-2.1 Exhibit 2.1 DATED AUGUST 20, 2025 XOMA ROYALTY CORPORATION XRA 5 CORP. AND MURAL ONCOLOGY PLC TRANSACTION AGREEMENT CONTENTS 1.   DEFINITIONSAND INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 15 2. RULE 2.7 ANNOUNCEMENT AND SCHEME DOCUMENT 17 2.1 Rule 2.7 Announcement 17    2.2 Scheme 18 2.3 Target Equity Award Holder Proposal 18 2.4 Confirmation of Closing Net Cash 19 2.5 Change in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2025 Mural Oncology pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 20, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File

Mural Oncology plc and Subsidiaries Consolidated Balance Sheet Data (in thousands) June 30, 2025 December 31, 2024 ASSETS Cash, cash equivalents, and marketable securities $ 77,094 $ 144,385 Prepaid expenses and other assets 2,493 8,542 Property and

EX-99.1 Exhibit 99.1 Mural Oncology Announces Second Quarter Financial Results and Provides Business Update Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) — Mural

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2025 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2025 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

PROXY STATEMENT IMPORTANT INFORMATION ABOUT THE AGM AND VOTING PROPOSAL NO. 1 PROPOSAL NO. 2 CORPORATE GOVERNANCE EXECUTIVE OFFICERS TRANSACTIONS WITH RELATED PERSONS SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT SHAREHOLDER PROPOSAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2025 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

Amendment No. 1 to Employment Agreement, dated as of February 15, 2025 by and between Mural Oncology, Inc. and Caroline Loew.

Exhibit 10.18 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Employment Agreement (as defined below) is dated as of February 15th, 2025, and entered into by and between Mural Oncology, Inc., (“Mural”), and Caroline Loew (the “Executive”). WHEREAS, Mural and the Executive entered into that certain Employment Agreement effective as of November 15, 2023, (

Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,”

INVESTOR PRESENTATION March 2025 Exhibit 99.2 Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended to identify forward-looking statements. Forward-looki

List of subsidiaries.

Exhibit 21.1 SUBSIDIARIES Name Jurisdiction Mural Oncology, Inc. (d/b/a Mural Biopharmaceuticals in New York and Mural Biopharmaceuticals, Inc. in Michigan) Delaware Mural Oncology Securities Corporation Massachusetts

Insider Trading Policy of Mural Oncology, Inc.

Exhibit 19.1 MURAL ONCOLOGY PLC INSIDER TRADING POLICY Mural Oncology plc (the “Company,” “we” or “our”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences as

Open Market Sale AgreementSM, dated as of March 11, 2025, by and between the Company and Jefferies LLC

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 11, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Mural Oncology plc, an Irish incorporated public limited company (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), the Company’s o

Mural Oncology plc and Subsidiaries Consolidated Balance Sheet Data

Exhibit 99.1 Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melan

Amendment No. 1 to Employment Agreement, dated as of February 15, 2025 by and between Mural Oncology, Inc. and Adam Cutler.

Exhibit 10.19 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Employment Agreement (as defined below) is dated as of February 15th, 2025, and entered into by and between Mural Oncology, Inc., (“Mural”), and Adam Cutler (the “Executive”). WHEREAS, Mural and the Executive entered into that certain Employment Agreement effective as of November 15, 2023, (th

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0.

As filed with the Securities and Exchange Commission on March 11, 2025

As filed with the Securities and Exchange Commission on March 11, 2025 Registration No.

Up to $75,000,000 Ordinary Shares

Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-283198 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED NOVEMBER 19, 2024) Up to $75,000,000 Ordinary Shares We have entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, dated March 11, 2025, relating to the sale of our ordinary shares, nominal value $0.01 per share. In acc

Amendment No. 1 to Employment Agreement, dated as of February 15, 2025 by and between Mural Oncology, Inc. and Vicki L. Goodman.

Exhibit 10.20 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Employment Agreement (as defined below) is dated as of February 15th, 2025, and entered into by and between Mural Oncology, Inc., (“Mural”), and Vicki L. Goodman (the “Executive”). WHEREAS, Mural and the Executive entered into that certain Employment Agreement effective as of November 15, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

e UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41837 Mural Oncolog

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Exhibit 99.1 Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected i

Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,”

INVESTOR PRESENTATION January 2025 Exhibit 99.2 Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended to identify forward-looking statements. Forward-loo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2025 Mural Oncology pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File

MURAL ONCOLOGY PLC 10 Earlsfort Terrace Dublin 2, D02 T380, Ireland

CORRESP MURAL ONCOLOGY PLC 10 Earlsfort Terrace Dublin 2, D02 T380, Ireland November 15, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

MURA / Mural Oncology plc / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation  or Carry Forward Rule Amount Registered  Proposed Maximum  Offering Price Per  Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration  Fee Carry Forward Form Type Carry Forward  File Number  Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be  Paid Debt Debt Securities (1) (1) (1) (1) (1) (1) —  —  —  —  Fees to Be  Paid Equity Ordinary Shares, nominal value $0.

Mural Oncology plc and Subsidiaries Consolidated Balance Sheet Data

Exhibit 99.1 Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4

Form of Senior Indenture

Exhibit 4.2 MURAL ONCOLOGY PLC and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicabl

Form of Subordinated Note

Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Senior Note

Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

As filed with the Securities and Exchange Commission on November 13, 2024

Table of Contents As filed with the Securities and Exchange Commission on November 13, 2024 Registration No.

Form of Subordinated Indenture

Exhibit 4.3 MURAL ONCOLOGY PLC and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapp

Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Exhibit 99.1 FOR IMMEDIATE RELEASE Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclose

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission Fi

Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,”

2024 virtual investor day: Clinical insights & clinician discussion September 26, 2024 Exhibit 99.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 20, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 Mural Oncology pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File

Mural Oncology plc and Subsidiaries Consolidated Balance Sheets (in thousands)

Exhibit 99.1 Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report readouts from Mural’s lead asset, nemvaleukin alfa, in two late-stage cli

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

MURA / Mural Oncology plc / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mural Oncology PLC (Name of Issuer) Common Stock (Title of Class of Securities) G63365103 (CUSIP Number) (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2024 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File Nu

MURA / Mural Oncology plc / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment

SC 13G/A 1 muraa370824.htm WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mural Oncology PLC (Name of Issuer) Common Stock (Title of Class of Securities) G63365103 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Mural Oncology plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File Num

Mural Oncology plc and Subsidiaries Consolidated Balance Sheets (in thousands)

Exhibit 99.1 Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a sing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

MURA / Mural Oncology plc / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment

SC 13G/A 1 muraa250824.htm WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mural Oncology PLC (Name of Issuer) Common Stock (Title of Class of Securities) G63365103 (CUSIP Number) April 30, 2024 (Date of Event which Requires Filing of this Statement) Check th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

MURA / Mural Oncology plc / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment

SC 13G/A 1 muraa140424.htm WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mural Oncology PLC (Name of Issuer) Common Stock (Title of Class of Securities) G63365103 (CUSIP Number) March 29, 2024 (Date of Event which Requires Filing of this Statement) Check th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2024 Mural Oncology plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File N

Mural Oncology plc Consolidated Balance Sheets (in thousands)

Exhibit 99.1 Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less f

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General The following description of the securities of Mural Oncology plc (“us,” “our,” “we” or the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is intended as a summary only and therefore is not a complete descriptio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

e UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41837 Mural Oncolog

Mural Oncology plc Senior Executive Cash Incentive Bonus Plan.

Exhibit 10.17 Execution Version mural oncology plc SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Mural Oncology plc (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and

Mural Oncology plc Compensation Recovery Policy

Exhibit 97.1 MURAL ONCOLOGY plc COMPENSATION RECOVERY POLICY Mural Oncology plc (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with rules issued by the United States Securities a

List of subsidiaries.

Exhibit 21.1 SUBSIDIARIES Name Jurisdiction Mural Oncology, Inc. (d/b/a Mural Biopharmaceuticals in New York and Mural Biopharmaceuticals, Inc. in Michigan) Delaware Mural Oncology Securities Corporation Massachusetts

Amendment to Employee Matters Agreement, dated as of December 14, 2023, by and between Alkermes plc and Mural Oncology plc.

Exhibit 10.3 Execution Version AMENDMENT TO EMPLOYEE MATTERS AGREEMENT This amendment (the “Amendment”) to that certain Employee Matters Agreement, dated November 13, 2023 (the “Employee Matters Agreement”), between Alkermes plc (“Alkermes”), an Irish public limited company, and Mural Oncology plc (“Mural”), an Irish public limited company, is entered into as of December 14, 2023 by and among Alke

IE000LK2BOB4 / Mural Oncology PLC / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-mura123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mural Oncology plc (Name of Issuer) Ordinary shares, nominal value $0.01 per share (Title of Class of Securities) G63365103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the

IE000LK2BOB4 / Mural Oncology PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01499-muraloncologyplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Mural Oncology PLC Title of Class of Securities: Common Stock CUSIP Number: G63365103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat

Mural Oncology plc 2024 Inducement Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 99.1 to the registrant’s Form S-8 filed with the SEC on January 16, 2024. (File No. 333-276524)).

Exhibit 99.1 MURAL ONCOLOGY PLC 2024 INDUCEMENT STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Mural Oncology plc 2024 Inducement Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers and employees of Mural Oncology plc, an Irish public limited company (the “Company”), and its A

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, nominal value $0.

As filed with the Securities and Exchange Commission on January 16, 2024

Form S-8 As filed with the Securities and Exchange Commission on January 16, 2024 Registration No.

MURA / Mural Oncology plc / WESTFIELD CAPITAL MANAGEMENT CO LP - WESTFIELD CAPITAL MANAGEMENT COMPANY, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Mural Oncology PLC (Name of Issuer) Common Stock (Title of Class of Securities) G63365103 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]

Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,”

INVESTOR PRESENTATION January 2024 Exhibit 99.1 Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended to identify forward-looking statements. Forward-loo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Mural Oncology pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Ireland 98-1748617 (State or other jurisdiction of incorporation or organization) (I.

MURA.V / Mural Oncology plc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv0002-muraloncologyplc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Mural Oncology PLC Title of Class of Securities: Common Stock CUSIP Number: G63365103 Date of Event Which Requires Filing of this Statement: November 30, 2023 Check the appropriate box to designate the rule pursuant to wh

Amended and Restated Memorandum and Articles of Association of Mural Oncology plc (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-3.1 Exhibit 3.1 Companies Act 2014 A PUBLIC LIMITED COMPANY CONSTITUTION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY (Amended by Special Resolution dated 26 October 2023) Incorporated 31 May 2017 Companies Act 2014 A PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY 1. The name of the Company is Mural Oncology public limited company. 2. The registered office

Assignment and Assumption of Lease, dated as of November 13, 2023, by and between Alkermes, Inc. and Mural Oncology, Inc. (incorporated by reference to Exhibit 10.9 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.9 Exhibit 10.9 ASSIGNMENT AND ASSUMPTION OF LEASE This ASSIGNMENT AND ASSUMPTION OF LEASE (this “Assignment”) is made and entered into as of the 13th day of November, 2023, by and between ALKERMES, INC., a Pennsylvania corporation (“Assignor”) and MURAL ONCOLOGY, INC., a Delaware Corporation (“Assignee”). WITNESSETH: A. Assignor and GI TC 850 Winter Street, LLC, a Delaware limited liability

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 Mural Oncology

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission Fil

INFORMATION STATEMENT MURAL ONCOLOGY PLC

EX-99.1 Exhibit 99.1 Dear Alkermes plc Shareholder: In November 2022, we announced a transformative milestone for Alkermes plc—our intent to separate our neuroscience and oncology businesses. The main strategic objectives of the separation are to unlock value, enhance the operational performance and strategic flexibility of each business and simplify capital allocation decision-making. We believe

Lease between Alkermes, Inc. and PDM Unit 850, LLC, dated as of April 22, 2009, as amended (incorporated by reference to Exhibit 10.8 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837))

EX-10.8 Exhibit 10.8 Execution Version LEASE BETWEEN PDM UNIT 850, LLC AND ALKERMES, INC. FOR PREMISES LOCATED AT 850 AND 852 WINTER STREET RESERVOIR WOODS, WALTHAM, MASSACHUSETTS TABLE OF CONTENTS Page Article 1. Premises — Term of Lease 1 Section 1.01 Premises 1 Section 1.02 Special Appurtenant Rights 1 Section 1.03 Term Commencement 2 Article 2. Rent 4 Section 2.01 Base Rent 4 Section 2.02 Addi

Employment Agreement, effective as of November 15, 2023, by and between Mural Oncology, Inc. and Adam Cutler (incorporated by reference to Exhibit 10.5 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.5 Exhibit 10.5 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is between Mural Oncology, Inc., a Delaware Corporation, (“Mural”), and Adam Cutler (the “Executive”), and is effective as of November 15, 2023 (the “Effective Date”). WHEREAS, Mural desires to employ the Executive and the Executive desires to be employed by Mural commencing on the Start Date (as defined below) on th

Transition Services Agreement, dated as of November 13, 2023, by and between Mural Oncology, Inc. and Alkermes, Inc. (incorporated by reference to Exhibit 10.4 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.4 Exhibit 10.4 Execution Version TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. and ALKERMES, INC. Dated as of November 13, 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 3 Section 2.1 General 3 Section 2.2 Standard for Services 3 Section 2.3 Protection of Mural US Information Systems 4 Section 2.4 Tra

Separation Agreement, dated as of November 13, 2023, by and between Alkermes plc and Mural Oncology plc (incorporated by reference to Exhibit 2.1 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-2.1 Exhibit 2.1 Execution Version SEPARATION AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of November 13, 2023 SEPARATION AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 16 ARTICLE II THE SEPARATION 18 Section 2.1 General 18 Section 2.2 Transfer of Assets; Assumption of Liabilities 18 Se

Transition Services Agreement, dated as of November 13, 2023, by and between Alkermes, Inc. and Mural Oncology, Inc. (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.3 Exhibit 10.3 Execution Version TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. and MURAL ONCOLOGY, INC. Dated as of November 13, 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 3 Section 2.1 General 3 Section 2.2 Standard for Services 4 Section 2.3 Protection of Alkermes US Information Systems 5 Section 2.4

Tax Matters Agreement, dated as of November 13, 2023, by and between Alkermes plc and Mural Oncology plc (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.1 Exhibit 10.1 Execution Version TAX MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of November 13, 2023 TAX MATTERS AGREEMENT ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II LIABILITY FOR TAXES AND DISTRIBUTION LOSSES 10 Section 2.1 General Rule 10 Section 2.2 Allocation Of Taxes For Pre-Distribution Periods 10 ARTICLE III PREPARATION AND FILING OF TA

Employee Matters Agreement, dated as of November 13, 2023, by and between Alkermes plc and Mural Oncology plc (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.2 Exhibit 10.2 Execution Version EMPLOYEE MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of November 13, 2023 EMPLOYEE MATTERS AGREEMENT TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II TRANSFER OF MURAL EMPLOYEES; GENERAL PRINCIPLES 5 Section 2.1 Transfer of Employment to Mural of Additional Employees; Post-Effective Time Transfe

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

EX-99.2 Exhibit 99.2 Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational

Employment Agreement, effective as of November 15, 2023, by and between Mural Oncology, Inc. and Vicki L. Goodman (incorporated by reference to Exhibit 10.7 to the registrant’s Current Report on Form 8-K filed with the SEC on November 15, 2023 (File No. 001-41837)).

EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is between Mural Oncology, Inc., a Delaware Corporation, (“Mural”), and Vicki L. Goodman (the “Executive”), and is effective as of November 15, 2023 (the “Effective Date”). WHEREAS, Mural desires to employ the Executive and the Executive desires to be employed by Mural commencing on the Start Date (as defined below)

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0.

As filed with the Securities and Exchange Commission on November 13, 2023

As filed with the Securities and Exchange Commission on November 13, 2023 Registration No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2023 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File

Mural Oncology plc 10 Earlsfort Terrace Dublin 2, D02 T380, Ireland

Mural Oncology plc 10 Earlsfort Terrace Dublin 2, D02 T380, Ireland October 27, 2023 VIA EDGAR U.

Mural Oncology plc 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the registrant’s Registrant Statement on Form 10/A filed with the SEC on October 26, 2023 (File No. 001-41837)).

Exhibit 10.11 MURAL ONCOLOGY PLC 2023 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Mural Oncology plc 2023 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Mural Oncology plc (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase ordinary shares, par value $0.01 per share, of the Company (“Shares”). An aggregate of 100,

Form of Mural Oncology plc Compensation Recovery Policy

Exhibit 10.12 MURAL ONCOLOGY PLC COMPENSATION RECOVERY POLICY Mural Oncology plc (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with rules issued by the United States Securities

As filed with the U.S. Securities and Exchange Commission on October 26, 2023.

As filed with the U.S. Securities and Exchange Commission on October 26, 2023. File No. 001-41837 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Mural Oncology plc (Exact name of Registrant as specified in its charter) Ireland 98-

Information Statement of Mural Oncology plc, preliminary and subject to completion, dated October 26, 2023

Table of Contents Exhibit 99.1 Dear Alkermes plc Shareholder: In November 2022, we announced a transformative milestone for Alkermes plc—our intent to separate our neuroscience and oncology businesses. The main strategic objectives of the separation are to unlock value, enhance the operational performance and strategic flexibility of each business and simplify capital allocation decision-making. W

Form of Employment Agreement by and between Mural Oncology, Inc. and Adam Cutler

Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is between Mural Oncology, Inc., a Delaware Corporation, (“Mural”), and Adam Cutler (the “Executive”), and is effective as of (the “Effective Date”). WHEREAS, Mural desires to employ the Executive and the Executive desires to be employed by Mural commencing on the Start Date (as defined below) on the terms and conditions con

Mural Oncology plc 2023 Stock Option and Incentive Plan, and forms of award certificates thereunder (incorporated by reference to Exhibit 10.8 to the registrant’s Registration Statement on Form 10/A filed with the SEC on October 26, 2023 (File No. 001-41837)).

Exhibit 10.8 MURAL ONCOLOGY PLC 2023 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Mural Oncology plc 2023 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Mural Oncology plc, an Irish public limited company (the “Compa

Form of Employment Agreement by and between Mural Oncology, Inc. and Vicki L. Goodman

Exhibit 10.14 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is between Mural Oncology, Inc., a Delaware Corporation, (“Mural”), and Vicki L. Goodman (the “Executive”), and is effective as of [      ] (the “Effective Date”). WHEREAS, Mural desires to employ the Executive and the Executive desires to be employed by Mural commencing on the Start Date (as defined below) on the terms and

Form of Mural Oncology plc Compensation Recovery Policy

Exhibit 10.12 MURAL ONCOLOGY PLC COMPENSATION RECOVERY POLICY Mural Oncology plc (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with rules issued by the United States Securities

Form of Employee Matters Agreement by and between Alkermes plc and Mural Oncology plc

Exhibit 10.4 EMPLOYEE MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of [•], 2023 EMPLOYEE MATTERS AGREEMENT TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II TRANSFER OF MURAL EMPLOYEES; GENERAL PRINCIPLES 5 Section 2.1 Transfer of Employment to Mural of Additional Employees; Post-Effective Time Transfers; Independent Contractors 5 Sect

Form of Transition Services Agreement by and between Alkermes, Inc. and Mural Oncology, Inc.

Exhibit 10.1 TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. and MURAL ONCOLOGY, INC. Dated as of [•], 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 4 Section 2.1 General 4 Section 2.2 Standard for Services 4 Section 2.3 Protection of Alkermes US Information Systems 5 Section 2.4 Transitional Nature of the Service

Form of Transition Services Agreement by and between Mural Oncology, Inc. and Alkermes, Inc.

Exhibit 10.2 TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. and ALKERMES, INC. Dated as of [•], 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 3 Section 2.1 General 3 Section 2.2 Standard for Services 4 Section 2.3 Protection of Mural US Information Systems 4 Section 2.4 Transitional Nature of the Services;

Employment Agreement, effective as of November 15, 2023, by and among Mural Oncology plc, Mural Oncology, Inc. and Dr. Caroline Loew (incorporated by reference to Exhibit 10.10 to the registrant’s Registration Statement on Form 10 filed with the SEC on October 10, 2023 (File No. 001-41837)).

Exhibit 10.10 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is among Alkermes, Inc., a Pennsylvania corporation (including its parent, subsidiaries and other affiliates and its and their successors and assigns, “Alkermes”), Caroline Loew (the “Executive”), and, effective as of the Mural Effective Date (as defined below), Mural Oncology, Inc., a Delaware corporation

Form of Mural Oncology plc Senior Executive Cash Incentive Bonus Plan

Exhibit 10.13 MURAL ONCOLOGY PLC SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Mural Oncology plc (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to thos

Form of Separation Agreement by and between Alkermes plc and Mural Oncology plc

Exhibit 2.1 SEPARATION AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of [•], 2023 SEPARATION AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 16 ARTICLE II THE SEPARATION 18 Section 2.1 General 18 Section 2.2 Transfer of Assets; Assumption of Liabilities 18 Section 2.3 Treatment of Shared Con

As filed with the U.S. Securities and Exchange Commission on October 10, 2023.

As filed with the U.S. Securities and Exchange Commission on October 10, 2023. File No. 001-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Mural Oncology plc (Exact name of Registrant as specified in its charter) Ireland 98-1748617 (State or o

Form of Indemnification Agreement between Mural Oncology, Inc. and individual officers

Exhibit 10.7 MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Mural Oncology, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS WHEREAS, the Company and Mural Oncology plc, a public limited company incorporated in Ireland (the “Parent”), desire to attract and retain the services of high

Form of Deed of Indemnification between Mural Oncology plc and individual directors and officers

Exhibit 10.5 MURAL ONCOLOGY PLC FORM OF DEED OF INDEMNIFICATION This Deed of Indemnification (“Deed”) is made as of , 20 by and between Mural Oncology plc, a public limited company incorporated in Ireland (registered number [●]) having its registered office at [●] (the “Company”) and [ ] ( “Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified i

Exhibit 99.1

Table of Contents Dear Alkermes plc Shareholder: In November 2022, we announced a transformative milestone for Alkermes plc—our intent to separate our neuroscience and oncology businesses.

Form of Notice of Internet Availability of Information Statement Materials

Exhibit 99.2 Important Notice Regarding the Availability of Materials ALKERMES PLC You are receiving this communication because you hold ordinary shares of Alkermes plc (“Alkermes”). Alkermes has released informational materials related to the separation of its oncology business into a new, independent public company to be known as Mural Oncology plc (“Mural”). The separation will be effected thro

Form of Amended and Restated Memorandum and Articles of Association of Mural Oncology plc

EXHIBIT 3.1 Companies Act 2014 A PUBLIC LIMITED COMPANY CONSTITUTION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY (Amended by Special Resolution dated [●] 2023) Incorporated 31 May 2017 Companies Act 2014 A PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY 1. The name of the Company is Mural Oncology public limited company. 2. The registered office of the Compan

List of Subsidiaries of Mural Oncology plc

Exhibit 21.1 List of Subsidiaries of Mural Oncology plc The following entities are expected to be subsidiaries of Mural Oncology plc upon completion of the separation from Alkermes plc as described in the information statement: Name of Subsidiary Jurisdiction Mural Oncology, Inc. Delaware

Form of Mural Oncology, Inc. Employment Agreement with executive officers

Exhibit 10.9 FORM OF EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is between Mural Oncology, Inc., a Delaware Corporation, (“Mural”), and [     ] (the “Executive”), and is effective as of [     ](the “Effective Date”). WHEREAS, Mural desires to employ the Executive and the Executive desires to be employed by Mural commencing on the Start Date (as defined below) on the terms and con

Form of Mural Oncology plc 2023 Stock Option and Incentive Plan, and forms of award certificates thereunder

Exhibit 10.8 MURAL ONCOLOGY PLC 2023 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Mural Oncology plc 2023 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Mural Oncology plc, an Irish public limited company (the “Compa

Form of Indemnification Agreement between Mural Oncology, Inc. and individual directors

Exhibit 10.6 MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Mural Oncology, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS WHEREAS, the Company and Mural Oncology plc, a public limited company incorporated in Ireland (the “Parent”), desire to attract and retain the services of high

Form of Tax Matters Agreement by and between Alkermes plc and Mural Oncology plc

Exhibit 10.3 TAX MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of [●], 2023 TAX MATTERS AGREEMENT ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II LIABILITY FOR TAXES AND DISTRIBUTION LOSSES 10 Section 2.1 General Rule 10 Section 2.2 Allocation Of Taxes For Pre-Distribution Periods 10 ARTICLE III PREPARATION AND FILING OF TAX RETURNS 11 Section 3.1 Alkermes’

Form of Mural Oncology plc 2023 Employee Stock Purchase Plan

Exhibit 10.11 MURAL ONCOLOGY PLC 2023 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Mural Oncology plc 2023 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Mural Oncology plc (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase ordinary shares, par value $0.01 per share, of the Company (“Shares”). An aggregate of [] S

TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. MURAL ONCOLOGY, INC. Dated as of [•], 2023

Exhibit 10.1 TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. and MURAL ONCOLOGY, INC. Dated as of [•], 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 4 Section 2.1 General 4 Section 2.2 Standard for Services 4 Section 2.3 Protection of Alkermes US Information Systems 5 Section 2.4 Transitional Nature of the Service

Confidential draft submission submitted to the Securities and Exchange Commission on September 22, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein re

Confidential draft submission submitted to the Securities and Exchange Commission on September 22, 2023.

MURAL ONCOLOGY PLC 2023 EMPLOYEE STOCK PURCHASE PLAN

Exhibit 10.11 MURAL ONCOLOGY PLC 2023 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Mural Oncology plc 2023 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Mural Oncology plc (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase ordinary shares, par value $0.01 per share, of the Company (“Shares”). An aggregate of [] S

Companies Act 2014 A PUBLIC LIMITED COMPANY MURAL ONCOLOGY PUBLIC LIMITED COMPANY (Amended by Special Resolution dated [●] 2023) Incorporated 31 May 2017

EXHIBIT 3.1 Companies Act 2014 A PUBLIC LIMITED COMPANY CONSTITUTION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY (Amended by Special Resolution dated [●] 2023) Incorporated 31 May 2017 Companies Act 2014 A PUBLIC LIMITED COMPANY MEMORANDUM OF ASSOCIATION of MURAL ONCOLOGY PUBLIC LIMITED COMPANY 1. The name of the Company is Mural Oncology public limited company. 2. The registered office of the Compan

MURAL ONCOLOGY PLC COMPENSATION RECOVERY POLICY

Exhibit 10.12 MURAL ONCOLOGY PLC COMPENSATION RECOVERY POLICY Mural Oncology plc (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with rules issued by the United States Securities

MURAL ONCOLOGY PLC SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN

Exhibit 10.13 MURAL ONCOLOGY PLC SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Mural Oncology plc (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to thos

SEPARATION AGREEMENT by and between ALKERMES PLC MURAL ONCOLOGY PLC Dated as of [•], 2023

Exhibit 2.1 SEPARATION AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of [•], 2023 SEPARATION AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 16 ARTICLE II THE SEPARATION 18 Section 2.1 General 18 Section 2.2 Transfer of Assets; Assumption of Liabilities 18 Section 2.3 Treatment of Shared Con

MURAL ONCOLOGY PLC 2023 STOCK OPTION AND INCENTIVE PLAN

Exhibit 10.8 MURAL ONCOLOGY PLC 2023 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Mural Oncology plc 2023 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Mural Oncology plc, an Irish public limited company (the “Compa

PRELIMINARY AND SUBJECT TO COMPLETION, DATED SEPTEMBER 22, 2023 INFORMATION STATEMENT MURAL ONCOLOGY PLC

Table of Contents Exhibit 99.1 Information contained herein is subject to completion or amendment. A Registration Statement on Form 10 relating to these securities has been filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. PRELIMINARY AND SUBJECT TO COMPLETION, DATED SEPTEMBER 22, 2023 INFORMATION STATEMENT MURAL ONCOLOGY PLC This information

TAX MATTERS AGREEMENT by and between ALKERMES PLC MURAL ONCOLOGY PLC Dated as of [●], 2023

Exhibit 10.3 TAX MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of [●], 2023 TAX MATTERS AGREEMENT ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II LIABILITY FOR TAXES AND DISTRIBUTION LOSSES 10 Section 2.1 General Rule 10 Section 2.2 Allocation Of Taxes For Pre-Distribution Periods 10 ARTICLE III PREPARATION AND FILING OF TAX RETURNS 11 Section 3.1 Alkermes’

TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. ALKERMES, INC. Dated as of [•], 2023

Exhibit 10.2 TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. and ALKERMES, INC. Dated as of [•], 2023 TRANSITION SERVICES AGREEMENT TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 General 1 ARTICLE II SERVICES 3 Section 2.1 General 3 Section 2.2 Standard for Services 4 Section 2.3 Protection of Mural US Information Systems 4 Section 2.4 Transitional Nature of the Services;

Confidential draft submission submitted to the Securities and Exchange Commission on August 24, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remai

Confidential draft submission submitted to the Securities and Exchange Commission on August 24, 2023.

MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT

Exhibit 10.6 MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Mural Oncology, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS WHEREAS, the Company and Mural Oncology plc, a public limited company incorporated in Ireland (the “Parent”), desire to attract and retain the services of high

PRELIMINARY AND SUBJECT TO COMPLETION, DATED AUGUST 24, 2023 INFORMATION STATEMENT MURAL ONCOLOGY PLC

Table of Contents Exhibit 99.1 Information contained herein is subject to completion or amendment. A Registration Statement on Form 10 relating to these securities has been filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. PRELIMINARY AND SUBJECT TO COMPLETION, DATED AUGUST 24, 2023 INFORMATION STATEMENT MURAL ONCOLOGY PLC This information sta

List of Subsidiaries of Mural Oncology plc

Exhibit 21.1 List of Subsidiaries of Mural Oncology plc The following entities are expected to be subsidiaries of Mural Oncology plc upon completion of the separation from Alkermes plc as described in the information statement: Name of Subsidiary Jurisdiction Mural Oncology, Inc. Delaware

MURAL ONCOLOGY PLC FORM OF DEED OF INDEMNIFICATION

Exhibit 10.5 MURAL ONCOLOGY PLC FORM OF DEED OF INDEMNIFICATION This Deed of Indemnification (“Deed”) is made as of , 20 by and between Mural Oncology plc, a public limited company incorporated in Ireland (registered number [●]) having its registered office at [●] (the “Company”) and [ ] ( “Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified i

MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT

Exhibit 10.7 MURAL ONCOLOGY, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Mural Oncology, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS WHEREAS, the Company and Mural Oncology plc, a public limited company incorporated in Ireland (the “Parent”), desire to attract and retain the services of high

EMPLOYMENT AGREEMENT

Exhibit 10.10 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is among Alkermes, Inc., a Pennsylvania corporation (including its parent, subsidiaries and other affiliates and its and their successors and assigns, “Alkermes”), Caroline Loew (the “Executive”), and, effective as of the Mural Effective Date (as defined below), Mural Oncology, Inc., a Delaware corporation

Confidential draft submission submitted to the Securities and Exchange Commission on August 1, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remain

Confidential draft submission submitted to the Securities and Exchange Commission on August 1, 2023.

Goodwin Procter

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 August 1, 2023 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Franklin Wyman, Vanessa Robertson, Lauren Hamill, and Suzanne Hayes Re: Mural Oncology Limited Amendment No.

PRELIMINARY AND SUBJECT TO COMPLETION, DATED AUGUST 1, 2023 INFORMATION STATEMENT MURAL ONCOLOGY LIMITED

Table of Contents Information contained herein is subject to completion or amendment.

PRELIMINARY AND SUBJECT TO COMPLETION, DATED JULY 14, 2023 INFORMATION STATEMENT MURAL ONCOLOGY LIMITED

Table of Contents Information contained herein is subject to completion or amendment.

Confidential draft submission submitted to the Securities and Exchange Commission on July 14, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains

Confidential draft submission submitted to the Securities and Exchange Commission on July 14, 2023.

July 14, 2023

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 July 14, 2023 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Franklin Wyman, Vanessa Robertson, Lauren Hamill, and Suzanne Hayes Re: Mural Oncology Limited Amendment No. 1

Goodwin Procter

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 16, 2023 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Franklin Wyman, Vanessa Robertson, Lauren Hamill, and Suzanne Hayes Re: Mural Oncology Limited Draft Registrat

Confidential draft submission submitted to the Securities and Exchange Commission on June 16, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains

Confidential draft submission submitted to the Securities and Exchange Commission on June 16, 2023.

PRELIMINARY AND SUBJECT TO COMPLETION, DATED JUNE 16, 2023 INFORMATION STATEMENT MURAL ONCOLOGY LIMITED

Table of Contents Information contained herein is subject to completion or amendment.

PRELIMINARY AND SUBJECT TO COMPLETION, DATED APRIL 14, 2023 INFORMATION STATEMENT MURAL ONCOLOGY LIMITED

Table of Contents Information contained herein is subject to completion or amendment.

Confidential draft submission submitted to the Securities and Exchange Commission on April 14, 2023. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remain

Confidential draft submission submitted to the Securities and Exchange Commission on April 14, 2023.

Goodwin Procter LLP

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 April 14, 2023 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Mural Oncology Limited Draft Registration Statement on Form 10 Ladies and Gentlemen: On behalf of Mural Oncology Limited (the “Company”), we are